Literature DB >> 21793943

Antifungal susceptibility of Candida albicans in biofilms.

Selma Tobudic1, Christina Kratzer, Andrea Lassnigg, Elisabeth Presterl.   

Abstract

Candida albicans are the most common fungi associated with biofilm-related infections. Biofilms are defined as microbial communities encased in a matrix of extracellular polymeric substances. The most important feature of biofilm growth is the high resistance to antimicrobial agents that can be up to 1000-fold greater than that of planktonic cells. This review discusses the factors affecting antifungal resistance as well as activity of mono- and combination therapy of different antifungal classes and antifungal activity in vitro and in vivo against C. albicans biofilms.
© 2011 Blackwell Verlag GmbH.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21793943     DOI： 10.1111/j.1439-0507.2011.02076.x

Source DB:  PubMed          Journal:  Mycoses        ISSN： 0933-7407            Impact factor:   4.377


  36 in total

Review 1.  Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans.

Authors:  Jinhui Cui; Biao Ren; Yaojun Tong; Huanqin Dai; Lixin Zhang
Journal:  Virulence       Date:  2015       Impact factor: 5.882

2.  Synergistic Antifungal Effect of Amphotericin B-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles and Ultrasound against Candida albicans Biofilms.

Authors:  Min Yang; Kaiyue Du; Yuru Hou; Shuang Xie; Yu Dong; Dairong Li; Yonghong Du
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 3.  Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?

Authors:  Danièle Maubon; Cécile Garnaud; Thierry Calandra; Dominique Sanglard; Muriel Cornet
Journal:  Intensive Care Med       Date:  2014-08-05       Impact factor: 17.440

Review 4.  Mechanisms of Candida biofilm drug resistance.

Authors:  Heather T Taff; Kaitlin F Mitchell; Jessica A Edward; David R Andes
Journal:  Future Microbiol       Date:  2013-10       Impact factor: 3.165

5.  [Candiduria! What now? : Therapy of urinary tract infections with Candida].

Authors:  H Hof
Journal:  Urologe A       Date:  2017-02       Impact factor: 0.639

6.  Characterization of biofilm formation and the role of BCR1 in clinical isolates of Candida parapsilosis.

Authors:  Srisuda Pannanusorn; Bernardo Ramírez-Zavala; Heinrich Lünsdorf; Birgitta Agerberth; Joachim Morschhäuser; Ute Römling
Journal:  Eukaryot Cell       Date:  2013-12-02

7.  Discovery of a Novel Dibromoquinoline Compound Exhibiting Potent Antifungal and Antivirulence Activity That Targets Metal Ion Homeostasis.

Authors:  Haroon Mohammad; Nehal H Elghazawy; Hassan E Eldesouky; Youssef A Hegazy; Waleed Younis; Larisa Avrimova; Tony Hazbun; Reem K Arafa; Mohamed N Seleem
Journal:  ACS Infect Dis       Date:  2018-02-02       Impact factor: 5.084

8.  Deletion of vacuolar proton-translocating ATPase V(o)a isoforms clarifies the role of vacuolar pH as a determinant of virulence-associated traits in Candida albicans.

Authors:  Summer M Raines; Hallie S Rane; Stella M Bernardo; Jessica L Binder; Samuel A Lee; Karlett J Parra
Journal:  J Biol Chem       Date:  2013-01-11       Impact factor: 5.157

9.  Biofilm formation by Candida albicans is inhibited by photodynamic antimicrobial chemotherapy (PACT), using chlorin e6: increase in both ROS production and membrane permeability.

Authors:  Moisés Lopes Carvalho; Ana Paula Pinto; Leandro José Raniero; Maricilia Silva Costa
Journal:  Lasers Med Sci       Date:  2017-10-09       Impact factor: 3.161

10.  Polymeric micelles with anti-virulence activity against Candida albicans in a single- and dual-species biofilm.

Authors:  Yassamin N Albayaty; Nicky Thomas; Paulina D Ramírez-García; Thomas P Davis; John F Quinn; Michael R Whittaker; Clive A Prestidge
Journal:  Drug Deliv Transl Res       Date:  2021-03-13       Impact factor: 4.617
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.